Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Testing for natriuretic peptide markers, such as B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP), has ...

Previous studies on the value of brain natriuretic peptide in diastolic dysfunction have been largely limited to male subjects. The authors found that female gender, in addition to diastolic ...

Notably, the Brain Natriuretic Peptide protein was identified as a significant heart attack predictor. This peptide can be identified with a relatively simple blood test. Additionally, this ...

Atrial natriuretic peptide (ANP) is similar to b-type natriuretic peptide (BNP) in the hemodynamic effects. ANP is not measured clinically unlike BNP. It is released in response to myocyte stretch ...

B-type natriuretic peptide is released by cardiac myocytes in response to wall stretch. There are many hemodynamic effects of BNP which are beneficial in the setting of decompensated congestive ...

The inactive N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) has been linked to ventricular dysfunction in the general population, and is predictive of cardiac events. Corteville ...

The clinical chemistry test is intended to help diagnose heart failure using the N-terminal pro b-type natriuretic peptide biomarker.

Achondroplasia, which affects around one in 20,000 babies, has just one approved treatment: BioMarin’s Voxzogo. However, new ...